Antibiotic Susceptibility of Bacterial Uro-Pathogens In Patients Attending Family Physicians" (In Vitro Study)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Urinary Tract Infections (UTIs)
- Sponsor
- Abbott
- Enrollment
- 350
- Locations
- 1
- Primary Endpoint
- Sensitivity of Uropathogens
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
This study is aiming to evaluate the sensitivity of uropathogens isolated in patients with community acquired UTI with Enoxacin in comparison to other antimicrobials. While Secondary objective is to study the spectrum of uropathogens responsible for community acquired UTI in local population
Detailed Description
Mid stream , clean catch urine specimens of patients with uncomplicated community acquired UTI sent to microbiology labs by treating consultants from filter clinics for evaluation of pathogens will be utilized for sensitivity analysis. Only the first positive urine culture obtained per sample will be included in the analysis to eliminate any possibility of recurrence and nosocomial infection. The polymicrobial cultures and cultures with multidrug-resistant uropathogens will not be included in the analysis. Cultures with common contaminants, including coagulase-negative staphylococci and hemolytic streptococci, and cultures with Candida growth will be excluded. . Data points to be collected will be date of collection, computer generated Lab #, age, gender,list of cultured organisms, sensitivity of organisms with antibiotics.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Samples from primary care clinics from patients who reports UTI symptoms and in which uropathogens are isolated will be included.
Exclusion Criteria
- •Samples from specialized, hospitalized or catheterized patients.
Outcomes
Primary Outcomes
Sensitivity of Uropathogens
Time Frame: 3 months
Sensitivity of identified organisms shall be noted by the zone size in millimeters of the cultured organisms. "Sensitive", "Intermediate" and "Resistant" labels shall be used as per Clinical Laboratory Standard Institute (CLSI) guidelines.
Secondary Outcomes
- Common UTI pathogens(3 months)